Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
SYDNEY, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed dosing the first healthy subjects at the highest concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327).
- SYDNEY, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed dosing the first healthy subjects at the highest concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327).
- “To be dosing at twice the speed of the last cohort to 3,000mg over 15 minutes via intravenous administration is a testament to the safety and tolerability profile of R327,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- “This marks another important clinical milestone for the company, as we push towards achieving R327’s potential as a first-line treatment for the millions of patients with from UTIs each year, which, if left untreated, may lead to urosepsis.”
An independent safety committee recently unanimously concluded that R327 is safe and well tolerated in healthy male and female subjects at an infusion rate of 3,000mg via intravenous administration over 30 minutes. - Since the previous cohort dosed, the committee approved a faster infusion rate, double that of what was previously delivered at 30 minutes, now being delivered at 3,000mg over 15 minutes.